Roche

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

ICON, Roche in technology partnership

Tuesday, March 6, 2012 01:27 PM

Global CRO ICON has been selected by Roche as its technology partner for storing and managing medical images collected during the company’s clinical research programs.

More... »

Ventana receives FDA clearance for Ki-67 (30-9) image analysis

Tuesday, March 6, 2012 06:06 AM

The FDA has granted Ventana Medical Systems, a member of the Roche Group, 510(k) clearance for its Ventana Companion Algorithm Ki-67 (30-9) image analysis application used with the Ventana iScan Coreo Au scanner running Virtuoso software.

More... »

Roche extends Illumina tender offer

Monday, February 27, 2012 03:17 PM

Roche has extended its cash tender offer to acquire all outstanding shares of Illumina at $44.50 per share to 6 p.m., Eastern Standard Time, on March 23, 2012.

More... »

Illumina’s board unanimously rejects Roche’s offer

Wednesday, February 8, 2012 12:52 PM

Illumina’s board of directors has thoroughly reviewed Roche’s unsolicited tender offer with the assistance of its financial and legal advisors and, according to the company, has unanimously determined that the $44.50 per share cash offer is grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina’s stockholders.

More... »

Illumina adopts stockholder Rights Agreement in response to Roche acquisition plan

Thursday, January 26, 2012 01:22 PM

San Diego-based Illumina said its board of directors has adopted a Rights Agreement, pursuant to which one preferred stock purchase right will be distributed as a dividend on each share of Illumina common stock held of record as of the close of business Feb. 6, 2012 (the “Rights”).

More... »

Roche offers to acquire Illumina to strengthen its diagnostics

Wednesday, January 25, 2012 03:11 PM

Roche is proposing to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.

More... »

Bayer, Ventana collaborate on test for personalized cancer therapy

Wednesday, January 18, 2012 12:05 PM

Bayer Pharma has collaborated with Ventana Medical Systems, a member of the Roche Group, to develop a molecular companion diagnostic test to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC).

More... »

Roche, Xenon ink $646 million pain pact

Friday, January 13, 2012 12:15 PM

Roche’s Genentech unit plans to discover compounds and diagnostics for treatment of pain by collaborating with Xenon Pharmaceuticals, based in Vancouver.

More... »

Wheeler joins Acetylon

Monday, December 12, 2011 02:20 PM

Acetylon Pharmaceuticals has named Catherine A. Wheeler, MD, vice president, clinical development. Wheeler will have responsibility for all clinical development functions of the company, including current and future clinical trials of Acetylon’s HDAC6 selective drug candidate, ACY-1215, in multiple myeloma as well as other potential hematologic and solid tumor disease indications. She will also lead the clinical development of future drug candidates in inflammatory and neurodegenerative diseases.

More... »